Checkpoint Therapeutics Stock Total Asset

CKPT Stock  USD 2.95  0.18  5.75%   
Checkpoint Therapeutics fundamentals help investors to digest information that contributes to Checkpoint Therapeutics' financial success or failures. It also enables traders to predict the movement of Checkpoint Stock. The fundamental analysis module provides a way to measure Checkpoint Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Checkpoint Therapeutics stock.
Last ReportedProjected for Next Year
Total Assets4.8 M4.6 M
Total Assets is likely to drop to about 4.6 M in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Checkpoint Therapeutics Company Total Asset Analysis

Checkpoint Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Checkpoint Therapeutics Total Asset

    
  5.38 M  
Most of Checkpoint Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Checkpoint Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Checkpoint Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Checkpoint Therapeutics is extremely important. It helps to project a fair market value of Checkpoint Stock properly, considering its historical fundamentals such as Total Asset. Since Checkpoint Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Checkpoint Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Checkpoint Therapeutics' interrelated accounts and indicators.
0.870.68-0.050.410.230.240.581.00.580.73-0.220.250.180.50.50.62
0.870.390.39-0.040.2-0.270.240.870.240.47-0.510.37-0.260.770.770.65
0.680.39-0.590.430.030.560.860.680.860.580.38-0.220.58-0.2-0.20.09
-0.050.39-0.59-0.680.09-0.86-0.71-0.05-0.71-0.5-0.770.5-0.920.640.640.1
0.41-0.040.43-0.680.370.870.680.410.680.640.44-0.170.7-0.24-0.240.18
0.230.20.030.090.370.040.30.230.30.130.20.12-0.140.030.03-0.1
0.24-0.270.56-0.860.870.040.660.240.660.470.57-0.220.89-0.53-0.53-0.08
0.580.240.86-0.710.680.30.660.581.00.710.65-0.350.62-0.28-0.280.09
1.00.870.68-0.050.410.230.240.580.580.73-0.220.250.180.50.50.62
0.580.240.86-0.710.680.30.661.00.580.710.65-0.350.62-0.28-0.280.09
0.730.470.58-0.50.640.130.470.710.730.710.15-0.150.570.30.30.73
-0.22-0.510.38-0.770.440.20.570.65-0.220.650.15-0.530.57-0.8-0.8-0.51
0.250.37-0.220.5-0.170.12-0.22-0.350.25-0.35-0.15-0.53-0.250.510.510.15
0.18-0.260.58-0.920.7-0.140.890.620.180.620.570.57-0.25-0.43-0.430.05
0.50.77-0.20.64-0.240.03-0.53-0.280.5-0.280.3-0.80.51-0.431.00.79
0.50.77-0.20.64-0.240.03-0.53-0.280.5-0.280.3-0.80.51-0.431.00.79
0.620.650.090.10.18-0.1-0.080.090.620.090.73-0.510.150.050.790.79
Click cells to compare fundamentals
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Checkpoint Total Assets

Total Assets

4.6 Million

At this time, Checkpoint Therapeutics' Total Assets are comparatively stable compared to the past year.
Based on the latest financial disclosure, Checkpoint Therapeutics has a Total Asset of 5.38 M. This is 99.93% lower than that of the Biotechnology sector and 99.73% lower than that of the Health Care industry. The total asset for all United States stocks is 99.98% higher than that of the company.

Checkpoint Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Checkpoint Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Checkpoint Therapeutics could also be used in its relative valuation, which is a method of valuing Checkpoint Therapeutics by comparing valuation metrics of similar companies.
5.4M2.1M166.6M479.4M100%
Checkpoint Therapeutics is currently under evaluation in total asset category among its peers.

Checkpoint Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Checkpoint Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Checkpoint Therapeutics' managers, analysts, and investors.
56.2%
Environmental
60.6%
Governance
Social

Checkpoint Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Checkpoint Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Checkpoint Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Checkpoint Therapeutics' value.
Shares
Wealth Enhancement Advisory Services, Llc2024-12-31
130 K
Omers Administration Corp2024-12-31
116.9 K
Bank Of America Corp2024-12-31
90 K
Royal Bank Of Canada2024-12-31
89.9 K
Legacy Wealth Asset Management, Llc2024-12-31
85 K
Envestnet Asset Management Inc2024-09-30
83.6 K
Two Sigma Investments Llc2024-12-31
73 K
Northern Trust Corp2024-12-31
72.6 K
Squarepoint Ops Llc2024-12-31
71.9 K
Armistice Capital, Llc2024-12-31
4.5 M
Vanguard Group Inc2024-12-31
1.9 M

Checkpoint Fundamentals

Return On Equity-12.2
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,500%-1,000%-500%0%500%1,000%
Return On Asset-6.34
Operating Margin(798.17) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%2,500%
Current Valuation148.14 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Shares Outstanding48.13 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%
Shares Owned By Insiders30.04 %
Shares Owned By Institutions22.34 %
Number Of Shares Shorted7.76 M
Price To Earning(7.60) X
Price To Book8.56 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%-100%0%100%200%
Price To Sales3,252 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%
Revenue103 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%500%
Gross Profit(27.59 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%
EBITDA(52.15 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Net Income(51.85 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Cash And Equivalents30.89 M
Cash Per Share0.33 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Total Debt18.43 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Debt To Equity0.1 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Current Ratio1.30 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Book Value Per Share(0.28) X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120%-100%-80%-60%-40%-20%
Cash Flow From Operations(47.59 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%
Short Ratio9.03 X
Earnings Per Share(1.83) X
Target Price12.0
Number Of Employees23
Beta1.36
Market Capitalization152.85 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Total Asset5.38 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Retained Earnings(314.33 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Working Capital(13.05 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset46.85 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Liabilities2.89 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset5.38 M

About Checkpoint Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Checkpoint Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Checkpoint Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Checkpoint Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.